99
Views
9
CrossRef citations to date
0
Altmetric
Review

Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials

, , , , , & show all
Pages 3061-3078 | Published online: 16 Apr 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Chia-Ding Hou & Ti-Sung Yang. (2023) Distribution of weighted Lancaster’s statistic for combining independent or dependent P-values, with applications to human genetic studies. Communications in Statistics - Theory and Methods 52:20, pages 7442-7454.
Read now
Federica Tomao, Serena Maria Boccia, Carolina Maria Sassu, Martina Chirra, Innocenza Palaia, Maria Cristina Petrella, Violante Di Donato, Nicoletta Colombo & Pierluigi Benedetti Panici. (2020) First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research. Cancer Management and Research 12, pages 5479-5489.
Read now

Articles from other publishers (7)

Peeyush Prasad, Shyam Aggarwal & Shivani Arora Mittal. 2024. Biomarkers in Cancer Detection and Monitoring of Therapeutics. Biomarkers in Cancer Detection and Monitoring of Therapeutics 257 274 .
Ma Ida Mohmaed Ali, Maaike A. C. Bruin, Vincent O. Dezentjé, Jos H. Beijnen, Neeltje Steeghs & Alwin D. R. Huitema. (2023) Exposure–Response Analyses of Olaparib in Real-Life Patients with Ovarian Cancer. Pharmaceutical Research 40:5, pages 1239-1247.
Crossref
Jin-feng Wang, Lan-bo Zhao, Ya-di Bin, Kai-lu Zhang, Chao Sun, Yi-ran Wang, Xue Feng, Jing Ji, Li-song He, Fang-yao Chen & Qi-ling Li. (2022) Efficacy and Safety of Placebo During the Maintenance Therapy of Ovarian Cancer in Randomized Controlled Trials: A Systematic Review and Meta-analysis. Frontiers in Oncology 12.
Crossref
Hongmei Wang, Meng Wu, Haonan Liu, Hang Zhou, Yang Zhao, Yifan Geng, Bo Jiang, Kai Zhang, Bo Zhang, Zhengxiang Han & Xiuping Du. (2021) Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Frontiers in Oncology 11.
Crossref
Yangchun Xu, Lei Ding, Yuan Tian, Miaomiao Bi, Ning Han & Ling Wang. (2021) Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Frontiers in Oncology 10.
Crossref
Georgia Vasileiou, Maria J. Costa, Christopher Long, Iris R. Wetzler, Juliane Hoyer, Cornelia Kraus, Bernt Popp, Julius Emons, Marius Wunderle, Evelyn Wenkel, Michael Uder, Matthias W. Beckmann, Sebastian M. Jud, Peter A. Fasching, Alexander Cavallaro, André Reis & Matthias Hammon. (2020) Breast MRI texture analysis for prediction of BRCA-associated genetic risk. BMC Medical Imaging 20:1.
Crossref
Hossein Taghizadeh, Robert M. Mader, Leonhard Müllauer, Stefanie Aust, Stephan Polterauer, Heinz Kölbl, Veronika Seebacher, Christoph Grimm, Alexander Reinthaller & Gerald W. Prager. (2020) Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform. The Oncologist 25:7, pages e1060-e1069.
Crossref